Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Marsh K, van Til JA, Molsen-David E, Juhnke C, Hawken N, Oehrlein EM, et al. Health preference research in Europe: a review of its use in marketing authorization, reimbursement, and pricing decisions-report of the ISPOR Stated Preference Research Special Interest Group. Value Health. 2020;23(7):831–41. https://doi.org/10.1016/j.jval.2019.11.009.
2. Food and Drug Administration. Patient preference information—voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and De Novo requests, and inclusion in decision summaries and device labeling: guidance for industry, Food and Drug Administration staff, and other stakeholders. US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research; 2016.
3. Wale J, Scott AM, Hofmann B, Garner S, Low E, Sansom L. Why patients should be involved in health technology assessment. Int J Technol Assess Health Care. 2017;33(1):1–4. https://doi.org/10.1017/S0266462317000241.
4. Bouvy JC, Cowie L, Lovett R, Morrison D, Livingstone H, Crabb N. Use of patient preference studies in HTA decision making: a NICE perspective. Patient. 2020;13(2):145–9. https://doi.org/10.1007/s40271-019-00408-4.
5. van Overbeeke E, Forrester V, Simoens S, Huys I. Use of patient preferences in health technology assessment: perspectives of Canadian, Belgian and German HTA representatives. Patient. 2021;14(1):119–28. https://doi.org/10.1007/s40271-020-00449-0.